FDA
approval
·
FDA Grants Third Approval Under the National Priority Voucher Program
Summary
FDA-approved teclistamab in combination with daratumumab hyaluronidase-fihj (Tec-Dara) for adults with relapsed or refractory multiple myeloma after at least on…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
The U.S. Food and Drug Administration today approved teclistamab in combination with daratumumab hyaluronidase-fihj, Tec-Dara, to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.